Market Insights
The American College of Obstetricians and Gynecologists states that around 5%–25% of pregnant women experience postpartum depression in America. This growing prevalence is what primarily contributes to the lucrativeness of this market. Rising awareness among women with respect to postpartum depression has further catalyzed the market’s growth. Growing research activities among leading industries in developing suitable pharmacological treatment options increases the market’s attractiveness and the inclination of women toward timely treatment.
Antidepressants are prescribed for this condition at controlled dosages. No targeted therapy for postpartum depression has yet been approved owing to its complexity associated with lactating mothers. SAGE-547 (brexanolone), a phase 3 molecule, and SAGE-217, a phase 2 molecule, of SAGE Therapeutics, Inc. (Hummingbird Program), are being developed for the treatment of postpartum depression. In its phase, three trials, SAGE-547 (brexanolone) achieved positive primary results of a reduction in the HAM-D (Hamilton Depression Rating Scale) score compared to the placebo. A reduction in depressive symptoms within 30 days was observed during this trial. Approval of brexanolone would catalyze the overall postpartum depression treatment market in the forecast period from 2018 to 2026, as it would be the first approved targeted drug therapy for postpartum depression.
North America accounted for the largest market share in 2017 and continues its dominance through 2026 as well. North America witnessed a high number of teenage pregnancy cases, which is one of the primary reasons causing postpartum depression. As per the Centers for Disease Control and Prevention, a birth rate of 22.3 per 1000 women aged 15–19 years was reported. This growing incidence facilitates the overall market growth in North America. Asia Pacific projects sluggish growth in the postpartum depression treatment market during the forecast period due to a lack of awareness about the condition and lower patient acceptance of psychiatric conditions.
Suitable diagnosis for postpartum depression is one of the major unmet needs which could restrain the overall market growth. Additionally, the unacceptance and negligence of postpartum depression among patients could also have a negative impact on the market’s growth.
The global postpartum depression treatment market is segmented as follows:
By Drug Class
- Selective serotonin reuptake inhibitors
- Citalopram
- Escitalopram
- Fluoxetine
- Fluvoxamine
- Paroxetine
- Sertraline
- Serotonin and Norepinephrine Reuptake Inhibitors
- Desvenlafaxine
- Duloxetine
- Venlafaxine
- Other Antidepressants
- Bupropion
- Nefazodone
- Trazodone
- Mirtazapine
- Pipeline Molecules
- SAGE-547 (Phase III)
- SAGE-217 (Phase II)
- Ganaxolone (Phase II)
By Geography
- North America
- Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
- Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
The postpartum depression treatment market comprises various industrial players, namely Allergan Plc., Anikem Laboratories, Cipla Ltd., Eli Lilly and Company, Intas Pharmaceutical, Ltd., Marinus Pharmaceuticals, Inc., Mylan N.V., Pfizer, Inc., SAGE Therapeutics, Inc., Sun Pharmaceuticals Industries, Ltd., and others.
This report offers the following:
- An overview of the global postpartum depression treatment market
- Market outlook and in-depth analysis for the period from 2016 to 2026, with 2016 as the historical year and 2017 as the base year
- Annual growth rates for the period from 2018 to 2026 pertaining to the entire market and each segment have also been included in this report.
- A complete overview of pipeline molecules
- Qualitative information with respect to market drivers, opportunities, and restraints
- A complete understanding of the competitive landscape and profiles of key market players
